Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Diabetes Publish Ahead of Print published online ahead of print July 2, 2007
DOI: 10.2337/db07-0742

This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
db07-0742v1
56/10/2420    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Robertson, R. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Robertson, R. P.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Original Research

Estimation of beta cell mass by metabolic tests: necessary, but how sufficient?

R. Paul Robertson, MD1

1From the Pacific Northwest Research Institute and the Departments of Medicine and Pharmacology, University of Washington, 720 Broadway, Seattle, WA 98122

This Perspective questions the accuracy of metabolic testing as a measure of pancreatic islet beta cell mass in vivo in animals and in humans. The impetus for framing this question lies in the current intense interest in determining the fate of beta cell mass in transplanted islets (does it decrease, increase, or remain the same over time?) as well as ascertaining whether drugs that enhance incretin levels, and consequently enhance glucose-induced insulin secretion, might also preserve beta cell mass. An important methodology recently making scientific strides in this arena is positron emission tomography (PET). The central question this Perspective raises is whether it is likely that PET will provide significant advantages over the metabolic methods already in hand and routinely used to estimate beta cell mass. This article examines the fidelity with which published metabolic data correlate with independent measures of beta cell mass across multiple species. Correlation coefficients in the general range of r = 0.80 are routinely obtained, which are robust for in vivo research. Whether PET can significantly improve on these correlations, given its inherent limitations in measurement sensitivity, remains to be seen. It is clear that investigators developing PET methodology to estimate beta cell mass should at the same time incorporate metabolic measures into their studies so that side-by-side comparisons of accuracy of the two experimental approaches can be made.



Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
DiabetesHome page
S.-J. Kim, C. Nian, D. J. Doudet, and C. H.S. McIntosh
Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice
Diabetes, May 1, 2008; 57(5): 1331 - 1339.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.